Treatment of children with advanced-stage lymphoblastic lymphoma with pegaspargase
Zhang, Yu tong; Feng, Li Hua; Zhong, Xiao Dan; Wang, Li Zhe; Chang, Jian.
Iranian Journal of Pediatrics. 2014; 24 (1): 75-80
en Inglés
| IMEMR | ID: emr-152689
To evaluate the feasibility of Pegaspargase instead of L-asparaginase to treat children with advanced-stage lymphoblastic lymphoma [LBL] on the Berlin-Frankfurt-Munster [BFM]-95 protocol. Fifty-four newly diagnosed patients with stage III or IV LBL and without any treatment were enrolled in this study. Pegaspargase took place of L-asparaginase in BFM-95. The complications and treatment responses of patients treated on the BFM-95 protocol and modified BFM-95 protocol were then evaluated respectively. For LBL patients treated with BFM-95 protocol or modified BFM-95 protocol, the complete response, event-free survival, overall survival were similar. Stage 4 myelosuppression was the most common complication in both groups. Besides that, among 31 patients receiving modified BFM-95 protocol, coagulation defects were the most common complication. In contrast, anaphylactic reaction was the most common complication in the other 23 patients receiving BFM-95 protocol. Modified BFM-95 protocol is available to children with advanced-stage LBL with an equal outcome and enhances its compliance and decreases the incidence of anaphylactic reaction, compared to BFM-95 protocol. Coagulation defects are the major complication and tolerable in modified one
Biblioteca responsable:
EMRO
Documentos relacionados